Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma.
Phase of Trial: Phase I/II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Trebananib (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2017 Status changed from active, no longer recruiting to completed.
- 20 Apr 2017 Planned end date has been changed from 1 Dec 2016 to 1 May 2017
- 02 Feb 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.